FDA 483 - Bloodworks - May 03, 2024

An FDA inspection of Bloodworks in Seattle, WA, identified a significant deficiency in drug product component testing. The firm failed to perform specific identity tests for critical materials used in the manufacture of Cord Blood Units over several years. This indicates a lapse in quality control for essential components.